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Background: Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by a loss of
dopaminergic neurons in the substantia nigra, decreased striatal dopamine levels, and consequent
extrapyramidal motor dysfunction. The purpose of this study was to investigate potential in vivo protective effects
of Duzhong against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), as well as the bioactive constituents against
1-methyl-4-phenylpyridinium (MPP+) toxicity in vitro.
Methods: Male C57BL/6 mice were intraperitoneally administrated five consecutive injections of MPTP every 24 h at a
dose of 30 mg/kg to induce an in vivo PD model. Pole and traction tests were performed in mice to evaluate motor
deficits and bradykinesia after the final MPTP administration. The striatal levels of dopamine and its metabolites,
3,4-dihydroxyphenylacetic acid and homovanilic acid, were measured using a High-performance liquid
chromatography-electrical conductivity detector. To further explore the bioactive constituents and protective
mechanisms of Duzhong, seven compounds from Duzhong were tested on MPP+-treated SH-SY5Y cell lines
in vitro. A proteasome enzymatic assay and Cell Counting Kit-8 were performed to examine proteasomal activity
and cell viability of Duzhong-treated cells, respectively, after exposure to MPP+ and proteasome inhibitor MG132.
Results: Duzhong antagonized the loss of striatal neurotransmitters and relieved the associated anomaly in
ambulatory locomotor activity in PD mice after a 3-day pre-treatment of Duzhong crude extract. The five Duzhong
compounds attenuated MPP+-induced dysfunction of protease activity and reduced MG132-induced cytotoxicity.
Conclusion: Duzhong could serve as a potential candidate for PD treatment, and its mechanism involves the
amelioration of the ubiquitin-proteasome system.
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Parkinson’s disease (PD) is the second most common
neurodegenerative disease after Alzheimer’s disease. It
affects people aged over 55 years with psychological
and physical manifestations [1, 2]. Pathologically, it is
marked by the extensive loss of dopaminergic neurons
in the substantia nigra, which result in extrapyramidal
motor dysfunction, including tremor, rigidity, and
bradykinesia [3]. Although the etiology of PD is in-
completely understood, increasing evidence indicates* Correspondence: huliminth@126.com
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ubiquitin-proteasome system (UPS) dysfunction may
play a role in the principal molecular pathways of
PD [4, 5].
Impairment of the UPS is a cellular mechanism under-
lying the neurodegenerative process of PD. Pathologic-
ally, it is characterized by the substitution of a highly
soluble native neuronal protein with a progressively po-
lymerized protein, which forms to an altered conform-
ation. This results in intracellular aggregation, a process
associated with neuronal dysfunction and loss. The ab-
normal or misfolded proteins are normally targeted via
ubiquitination to the proteasome, where they are de-
graded in an adenosine triphosphate-dependent manneris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Compounds
Compound Abbreviation Formula Molecular weight
Betulinic acid Bea C30H48O3 456.71
Betulin Bet C30H50O2 442.71
Wogonin Wog C16H12O5 284.27
Oroxylin A Oro C16H12O5 284.26
Genipin Gen C11H14O5 226.23
Geniposidic Ged C17H24O10 378.37
Aucubin Auc C15H22O9 346.33
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tem, especially UPS, is a promising target in studying
the mechanisms of PD and the development of potential
therapeutic drugs. Two gene mutations, which are
unstable in the UPS and contribute to the demise of
dopaminergic neurons, encode parkin [7] and ubiquitin
C-terminal hydrolase-L1 (UCH-L1) [8]. The parkin gene
contains an N-terminal ubiquitin-like domain and a C-
terminal RING domain comprising two RING finger
motifs [5]. Like many other RING finger-containing
proteins, parkin can function as an E3 ubiquitin protein
ligase [9], which is an important part of the cellular
machinery that covalently tags target proteins with
ubiquitin [10]. UCH-L1 belongs to a family of deubiquiti-
nating enzymes, which might function as a dimerization-
dependent ubiquitin protein ligase and can maintain
ubiquitin homeostasis by promoting stability of ubiquitin
monomers [11, 12].
One way to study idiopathic PD in animals models in-
volves the use of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP), a precursor of the mitochondrial toxin
1-methyl-4-phenylpyridinium (MPP+), which targets
nigrostriatal dopaminergic neurons in the substantia
nigra in a pattern precipitating pathogenesis analogous
to human PD [13]. MPP+ mediates dopaminergic de-
generation by inhibiting electron transport chain ac-
tivity at complex I [14]. Loss of oxidative metabolism
and deficient production of adenosine-triphosphate
through the electron transport chain can bring about
rapid neuronal depolarization and a calcium-mediated
cascade of cell death [15, 16].
Herbal medicines are becoming more popular for im-
proving quality of life, with limited or no side effects
[17]. Currently, levodopa has been considered to be the
most clinically efficacious drug for PD treatment. How-
ever, long-term treatment with levodopa leads to dyskin-
esia [18, 19]. Therefore, alternative treatments for PD,
such as traditional Chinese medicine, were investigated.
Duzhong is from the bark of Eucommia ulmoides Oliv.,
and it has been widely used in traditional Chinese medi-
cine to treat hypertension [20, 21]. Modern molecular
research has shown that Duzhong prevents/decreases
hydrogen peroxide and amyloid β-induced neuronal
cytotoxicity [22, 23] as well as improves learning and mem-
ory [24]. It also protects neuronal cells from apoptosis in-
duced by the PD-related neurotoxin 6-hydroxydopamine
in SH-SY5Y cells [25], and improves scopolamine-induced
learning and memory deficits in mice [26]. However,
studies evaluating the neuroprotective role of Duzhong
in MPP+/MPTP PD experimental models have not been
conducted. In the present study, we investigated the
potential protective effects of Duzhong in vivo against
MPTP, and its bioactive constituents against MPP+ tox-
icity in vitro.Methods
Animals
Specific pathogen-free, adult, male, C57BL/6 mice
(25 ± 2 g body weight) were housed in standard cages
with wood shavings. Ten animals per cage were kept
at room temperature (25 °C) and the light schedule
was set for 12 h of light from 8:00 AM to 8:00 PM.
Food and water were freely available. The study was
conducted with the consent of the Ethics Committee
for the use of experimental animals as authorized by
the Tianjin University of Traditional Chinese Medicine
(Approval number: TCM-LAEC2014007).
Drugs
The bark of Eucommia ulmoides Oliv. was purchased
from Henan Drug Company (Henan, PR China) and
authenticated by Professor Li Tianxiang (Tianjin Univer-
sity of Traditional Chinese Medicine, Tianjin). A voucher
specimen (EUL090617) was deposited in the Institute
of Traditional Chinese Medicine, Tianjin University of
Traditional Chinese Medicine. The dried bark of E.
ulmoides was refluxed with 95 % ethanol twice (2 h each
time), and the ethanol extract was pooled, concentrated,
and dried using a vacuum (crude extract, yield 11 %).
Professor Su’s group (Tianjin University, Tianjin) iso-
lated 18 compounds from E. ulmoides ethanol extracts
and identified 16 structures. A detailed isolation proced-
ure of these compounds has been referenced by Yin
et al. [27]. We selected seven compounds (Table 1) with
molecular weight under 500 g/mol in vitro: betulinic
acid (Bea), betulin (Bet), wogonin (Wog), oroxylin A
(Oro), genipin (Gen), geniposidic (Ged), and aucubin
(Auc). The chemical structures are shown in Fig. 1 and
the 98 % purities were verified using High-performance
liquid chromatography-ultraviolet detector (HPLC-UV)
analysis. All compounds were tested at 10 μM, dissolved
in dimethyl sulfoxide at 10 mM as stock solution, and
diluted in culture medium.
Reagents
Fetal bovine serum (FBS), penicillin, and streptomycin
were purchased from Gibco Invitrogen. 1-methyl-4-
Fig. 1 Structures of the seven compounds isolated from Eucommia ulmoides. Two terpenes (betulinic acid and betulin), two flavonoids
(wogonin and oroxylin A), and three iridoids (genipin, geniposidic, and aucubin) were isolated from E. ulmoides and purities (98 %) were
verified using HPLC-UV analysis
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phenylpyridinium (MPP+) were purchased from Sigma-
Aldrich. 1640 medium was purchased from Hyclone. Cell
Counting Kit-8 (CCK-8) was purchased from Dojindo.
Fluorogenic Suc-LLVY-AMC was purchased from Boston
Biochem. All other chemicals were of analytical grade and
obtained from standard commercial suppliers. Madopar
was purchased from Roche, and each tablet contained
200 mg levodopa and 50 mg benserazide.
Animal grouping and treatment
Male mice (n = 48) were assigned to six groups: control
group, MPTP group (MPTP-treatment group), 150 mg/
kg group (150 mg Duzhong/kg body weight plus MPTP),
300 mg/kg group (300 mg Duzhong/kg body weight plus
MPTP), 600 mg/kg group (600 mg Duzhong/kg body
weight plus MPTP), and Madopar group (50 mg Mado-
par/kg body weight plus MPTP). Duzhong and Mado-
pars were dissolved in 0.5 % sodium carboxymethyl
cellulose. DuZhong and Madopar were orally adminis-
tered at the indicated concentrations every 24 h for 8
consecutive days. To evaluate the effects of Duzhong
and Madopar in the PD mouse model, MPTP (30 mg/kg) was intraperitoneally injected with five consecutive
doses every 24 h from day 4 to day 8; 1 h later, the mice
were orally administered Duzhong and Madopar. An
equal volume of saline, instead of MPTP, was injected
into the mice in the control group.
Neurobehavioral assessment
All animals in these studies underwent behavioral ana-
lysis after the final MPTP administration. The observer
was blinded to all groups until the completion of all
behavioral studies.
Pole test
The pole test for bradykinesia was conducted according
to a previously published method, with slight modifica-
tions [28]. The mouse was positioned downward at the
top of a vertical rough-surfaced pole (1-cm diameter,
80-cm height), and the duration from the time point that
the mouse started to move until the time point that the
mouse arrived at the floor (total locomotor activity) was
recorded. The pole test was performed three times
consecutively for each mouse, and the average value was
recorded.
Fig. 2 Protective effect of Duzhong against MPTP-induced behavioral dysfunction on a mouse model of Parkinson’s disease. The time period from
the final MPTP injection until the animal arrived on the floor (total locomotor activity) (a) was recorded with a limit of 30 s for the pole test. The
traction test measured hind limb grip power (b). Total locomotor activity time was significantly prolonged, and strength on the traction test was
decreased in MPTP-treated mice. Madopar and 600 mg/kg Duzhong significantly shortened the time to reach the platform and improved the
hind limb grip score. ##p < 0.01 vs. control group, *p < 0.05, **p < 0.01 vs. MPTP group, n = 8 animals/group
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The traction test evaluates muscle strength and equilib-
rium. When the mouse forepaws were placed on a rope,
hind limb placements were scored from 1 to 3, with the
lowest score indicating the most severe deficit. In short,
if both hind limbs seized the rope, the score was 3; if
one or no hind limb seized the rope, the score was 2 or
1, respectively.
Measurement of dopamine, 3,4-dihydroxyphenylacetic
acid (DOPAC), and homovanilic acid (HVA) levels in the
striatum
After completion of behavioral studies, all animals were
sacrificed for striatal catecholamine determination.
Dopamine, DOPAC, and HVA were measured as previ-
ously described [29]. Briefly, brains were quickly re-
moved, the left and right striatum were quickly dissected
from the brain, weighed, and sonicated in chilled
0.1 mol/L perchloric acid (per 1 mg tissue plus 10 mL
perchloric acid). The suspension was then vortexed, and
the striatum was centrifuged at 4 °C at 14,000 r/min for
20 min. The clear supernatant was collected and stored
at −80 °C until further HPLC analysis. Ten microliters of
supernatant was injected directly into the HPLC-ECDsystem using a Waters C18 reversed-phase analytic
column. The mobile phase contained 3 % acetonitrile,
19 % methanol, and 78 % water (11.56 mmol/L octane
sulfonic acid sodium, 100 mmol/L NaH2PO4, 0.095 mmol/
L EDTA-2Na).
Cell culture
Human neuroblastoma cells (SH-SY5Y) were purchased
from the Cell Center of the Institute of Basic Medical
Science Research (Chinese Academy of Medical Sci-
ences, Beijing, China). SH-SY5Y cells were cultured in
1640 supplemented with 15 % FBS, 100 U/mL penicil-
lin, and 100 μg/mL streptomycin. The medium was
replaced every 2 days. Cells were maintained at 37 °C
and 5 % CO2.
Proteasomal peptidase activity assay
The proteasome enzymatic assay was performed as pre-
viously described [30]. Briefly, SH-SY5Y cells were split
into 48-well plates at a density of 1 × 105/mL, and ex-
posed to 1 mM MPP+ with 10 μM of each compound
for 24 h. After treatment, yhr cells were collected,
washed, and lysed with hypotonic buffer (10 mM
HEPES, 5 mM MgCl2, 10 mM KCl, 1 % sucrose, snf
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genic Suc-LLVY-AMC (75 μM) in assay buffer (50 mM
Tris–HCl, 20 mM KCl, 5 mM MgOAc, and 10 mM
DTT, pH 7.6) at 37 °C or 30 min. The cleaved fluores-
cent product was measured at the excitation wavelength
of 380 nm and emission wavelength of 460 nm using a
fluorescent microplate reader (Flex Station 3, Molecular
Devices, CA, USA).
Viability assay
Cell viability was evaluated using a CCK-8 assay by
measuring absorbance. Cells were incubated with
200 μM MG132, a potent reversible inhibitor of the pro-
teasome, together with 10 μM of each compound for
24 h. Then, culture medium was removed and 10 %
CCK-8 was added to each well. Cells were then incu-
bated for 30 min at 37 °C, and the absorbance was mea-
sured at 450 nm using a microplate reader (Spectra III,
Tecan, Switzerland).Fig. 3 Effects of Duzhong on striatum dopamine, DOPAC, and HVA levels i
measured by HPLC-ECD. MPTP treatment significantly reduced striatal dopa
induced decrease of striatal dopamine and its metabolites in a dose-depen
group, n = 8 animals/groupStatistical analysis
Data were expressed as mean ± SD. Statistical analysis was
performed using one-way analysis of variance, as well as
the least significant difference test, using SPSS 13.0 soft-
ware. P < 0.05 was considered statistically significant.
Results
Effect of Duzhong on neurobehavior in MPTP-treated mice
We performed the pole and traction tests to evaluate
motor deficits and bradykinesia, respectively, in MPTP-
treated mice. The pole test showed that total locomotor
activity time was significantly prolonged after subchronic
MPTP treatment. Prophylactic treatment with Duzhong
(150, 300, and 600 mg/kg) shortened the time needed to
reach the platform, and results showed that 600 mg/kg
was the most effective (Fig. 2a). These results suggested
that Duzhong prevented MPTP-induced bradykinesia.
MPTP-treated mice showed decreased strength on the
traction test, but prophylactic treatment with Duzhongn MPTP-treated mice. Striatum dopamine, DOPAC, and HVA levels were
mine, DOPAC, and HVA levels. Duzhong treatment blocked the MPTP-
dent manner. ##p < 0.01 vs. control group, *p < 0.05, **p < 0.01 vs. MPTP
Guo et al. BMC Complementary and Alternative Medicine  (2015) 15:151 Page 6 of 8(150, 300, and 600 mg/kg) resulted in improved traction
test performance, suggesting that the initial lesions
caused by MPTP were prevented by prophylactic treat-
ment with Duzhong (Fig. 2b).
Duzhong blocks MPTP-induced loss of striatal dopamine
and its metabolites
We measured striatal levels of dopamine and its metabo-
lites, DOPAC and HVA, by HPLC-ECD. MPTP treat-
ment significantly reduced striatal dopamine, DOPAC,
and HVA levels. Duzhong (150, 300, and 600 mg/kg)
treatment blocked the MPTP-induced decrease of stri-
atal dopamine and its metabolites in a dose-dependent
manner (Fig. 3). These results indicated that Duzhong
pretreatment improved dopamine, DOPAC, and HVA
levels in the striatum of experimental PD mice.
Up-regulation of proteasomal activity by Duzhong
compounds
To determine the proteasomal activity in dopaminergic-
characteristic SH-SY5Y cells, a proteasome enzymatic
assay was used. Fig. 4a shows that MPP+ decreased pro-
teasome activity after 24 h treatment compared with the
control group. Treatment with Duzhong compounds
(Bet, Wog, Oro, Ged, and Auc) significantly reversed the
MPP+-induced reduction in proteasome activity.Fig. 4 Effect of Duzhong compounds on MPP+ or MG132-induced neuroto
exposed to 10 μM compound and 1 mM MPP+ or 200 μM MG132 for 24 h
were examined. Following treatment with seven compounds of Duzhong (10 μ
reversed MPP+-induced reduction in proteasome activity and attenuated the M
percentages of the control group. ##p< 0.01 vs. control group, *p< 0.05, **p< 0Effect of Duzhong compounds on cell death induced by
proteasome inhibitors
We further examined whether inhibition of the UPS en-
hanced MG132 toxicity. We added 200 μM MG132, a
potent reversible proteasome inhibitor, to SH-SY5Y cells
pretreated with Duzhong compounds for 24 h. Cell
survival, as indicated by the CCK-8 method, markedly
decreased in the presence of MG132 as shown in Fig. 4b.
Five out of seven compounds from Duzhong (Bet, Wog,
Oro, Ged, and Auc) attenuated the MG132-induced
dysfunction of protease activity and cytotoxicity at a
concentration of 10 μM. These results suggested that
impairment of the UPS by MG132 was attenuated by
Duzhong in SH-SY5Y cells.
Discussion
In the present study, we tested whether E. ulmoides ex-
tracts protected against motor function reductions in
MPTP-induced mice. Behavioral analysis was conducted
after the final injection. The results from the pole test
and traction test revealed that Duzhong (150, 300, and
600 mg/kg) increased motor activity of MPTP-treated
mice, and 600 mg/kg was the most effective (Fig. 2a).
Neurotransmitter secretion maintains normal neural
functions, although neuronal damage can affect neuro-
transmitter release [31]. Dopamine and its metabolitesxicity in the dopaminergic neuroblastoma SH-SY5Y cell line. Cells were
. Proteasomal peptidase activity (a) and cell viability (b) of SH-SY5Y cells
M each), five of the compounds (Bet, Wog, Oro, Ged, and Auc) significantly
G132-induced dysfunction of protease activity and cytotoxicity. Data are
.01 vs. MPP+ group, ap< 0.05, aap< 0.01 vs. MG132 group, n= 6
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functions. Loss of these neurotransmitters directly af-
fects physical movements and is considered a signature
feature of PD in humans or in animal models of the dis-
ease [32]. In this study, the HPLC-ECD method was
used to detect the effects of Duzhong on striatal dopa-
mine, DOPAC, and HVA in PD mice. Treatment with
Duzhong (150, 300, and 600 mg/kg) blocked the MPTP-
induced decrease of striatal dopamine and its metabo-
lites in a dose-dependent manner. The above findings
suggest that Duzhong has beneficial effects on the PD
mice model. However, its mechanisms and bioactive
constituents have not yet been characterized.
The UPS is essential to all eukaryotic cells [33], and
impairment elucidates mutations of key genes, including
α-synuclein, Parkin, and UCH-L1, some of which are
important in protein processing and degradation [34].
To date, a close relation of PD with a dysfunctional UPS
has been demonstrated.
Su et al. isolated 18 compounds from ethanol extracts
of E. ulmoides and identified structures of 16 compounds,
including two lignans, four iridoids, three flavonoids, two
triterpenoids, four anthraquinones, and a sterol [35]. The
present study selected seven compounds with a molecular
weight under 500 g/mol to investigate the protective mech-
anisms: betulinic acid (Bea), betulin (Bet), wogonin (Wog),
oroxylin A (Oro), genipin (Gen), geniposidic (Ged), and
aucubin (Auc). The chemical structures of these com-
pounds are shown in Fig. 1. All tested dosages of these
compounds were at 10 μM. Results demonstrated that
some of the compounds isolated from Duzhong, Bet, Wog,
Oro, Ged, and Auc, increased proteasome activity in
MPP+-treated SH-SY5Y cells, suggesting that toxic ac-
cumulation of intracellular proteins was detrimental
to neuronal cells and aberrant protein homeostasis
was prevented by Duzhong. In addition, MG132, a po-
tent reversible inhibitor of the proteasome, specifically
inhibits proteasomal peptidase activity and leads to
cell damage. This inhibition was remarkably attenu-
ated by 10 μM Bet, Wog, Oro, Ged, or Auc. These
data indicate that Duzhong was involved in the ameli-
oration of the UPS-dependent proteolysis system. The
bioactive constituents of Duzhong that were involved
in improving proteasome activity included Bet, Wog,
Oro, Ged, and Auc. In addition, Duzhong may impact
oxidative stress, which is also a major contributor to
PD pathology. However, further studies are needed to
elucidate the involved mechanisms.
Our study tested seven compounds, including two ter-
penes (Bea and Bet), two flavonoids (Wog and Oro), and
three iridoids (Gen, Ged, and Auc). Among them, a
terpene, two flavonoids, and two iridoids showed reduced
dysfunction of protease activity. Considering that the
UPS involves many different proteins, including ubiquitin,ubiquitin-activating enzyme (E1), ubiquitin-conjugating en-
zyme (E2), ubiquitin-protein ligase (E3), and its substrate, it
is possible that different compounds target different pro-
teins. Duzhong extract is a multi-component mixture.
Therefore, Duzhong might act on multiple targets, thereby
causing synergistic effects in vivo. To test this hypothesis,
further studies are needed.
Conclusions
These results suggest that Duzhong might serve as an
alternative and complementary treatment for PD and its
action mechanisms might be mediated by ameliorating
the UPS.
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